CEO GuideTen Decisions

From AI Activity to Pharma AI Advantage.

Ten choices on capital, use cases, people, IP and governance that determine whether AI creates measurable advantage in Pharma, not just measurable activity.

Takes 10 seconds. No spam.

What's inside the guide.

Ten CEO-level questions, from capital allocation to workforce redesign to governance.

  1. 01Posture: how aggressively should we move?
  2. 02Capital: where should we place our AI bets?
  3. 03Work: automate, augment or reinvent?
  4. 04People: what does AI mean for our workforce?
  5. 05Proprietary: what must remain ours?
  6. 06Technology: what should we actually own?
  7. 07Data: how much data work is really necessary?
  8. 08Governance: move fast without losing control
  9. 09Value: how do we know it is working?
  10. 10Agenda: the next 12 months
10 CEO-level questionsFrom capital allocation to workforce redesign to governance.
Built on primary researchBain, McKinsey, Deloitte, BCG and EY, 2024 to 2026.
A 12-month agendaSix concrete moves you can start this quarter.

5%

Only 5% of surveyed life-sciences organizations describe gen AI as a consistent competitive differentiator, despite universal experimentation.

McKinsey, 2025 · cited in the guide

More guides from The Decision Desk.

Seven guides, from the CEO agenda to the plant floor. Each is a ranked, sourced priority sequence, built on research from Bain, McKinsey, Deloitte, BCG, EY, ZS and MIT NANDA.

The Decision Desk · CEO Guide

CEO Guide for AI in Pharma.

Ten decisions. One download. Free, no spam, no sales pitch first.

Backed by Bain, McKinsey, Deloitte, BCG and EY research

The Decision Desk

Get the guide in your inbox.

Fill in your details below and we'll send the guide straight to your email.

You're set.

The guide is on its way to your inbox.

Oops! Something went wrong while submitting the form.